Showing results (131-140 of 196) with videos related to
Sort By:
Pageof 20
Blood|May 31, 2002
Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinosideElihu H Estey, Peter F Thall, Francis J Giles, et al.Cancer|March 7, 2006
Expression of Bcl-2 in gastrointestinal stromal tumors: correlation with progression-free survival in 81 patients treated with imatinib mesylateDejka M Steinert, Mauricio Oyarzo, Xuemei Wang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2007
Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylateJohn C McAuliffe, Alexander J F Lazar, Dan Yang, et al.Gynecologic Oncology|December 31, 2002
Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancersJon R Wiener, T Christopher Windham, Veronica C Estrella, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 15, 2014
Increasing chimerism after allogeneic stem cell transplantation is associated with longer survival timeXiaowen Tang, Gheath Alatrash, Jing Ning, et al.Journal of Surgical Oncology|July 15, 2024
Signet ring cells and conditional survival after trimodality therapy for esophageal adenocarcinomaKyle G Mitchell, Hope Feldman, Denái R Milton, et al.JAMA Network Open|July 12, 2022
Economic Evaluation of Cost and Time Required for a Platform Trial vs Conventional TrialsJay J H Park, Behnam Sharif, Ofir Harari, et al.Cancer|July 31, 2010
Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding studyMarcos de Lima, Sergio Giralt, Peter F Thall, et al.The Prostate|September 21, 2007
Employing the treatment-free interval of intermittent androgen ablation to screen candidate prostate cancer therapiesShifeng Mao, Danai D Daliani, Xuemei Wang, et al.Cancer|January 9, 2009
A possible association between aprotinin and improved survival after radical surgery for mesotheliomaPeter H Norman, Peter F Thall, Ronaldo V Purugganan, et al.Pageof 20